RT Journal Article
SR Electronic
T1 Detection of Circulating Glial Cells Enables Non-Invasive Diagnosis of Glial Malignancies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.06.22277300
DO 10.1101/2022.07.06.22277300
A1 O’Neill, Kevin
A1 Syed, Nelofer
A1 Crook, Timothy
A1 Dubey, Sudhir
A1 Potharaju, Mahadev
A1 Limaye, Sewanti
A1 Ranade, Anantbhushan
A1 Anichini, Giulio
A1 Patil, Darshana
A1 Murthy, Sudha S
A1 Akolkar, Dadasaheb
A1 Fulmali, Pooja
A1 Datta, Vineet
A1 Apurwa, Sachin
A1 John, Jinumary
A1 Srinivasan, Ajay
A1 Datar, Rajan
YR 2022
UL http://medrxiv.org/content/early/2022/07/10/2022.07.06.22277300.abstract
AB Diagnosis of primary glial malignancies (GLI-M) in individuals presenting with Intracranial Space Occupying Lesions (ICSOL) is based on histopathological evaluation (HPE) of tissue obtained by surgical resection or biopsy with attendant resource implications and risks. Approximately 70% of ICSOLs have non-malignant etiology and distinction from malignant lesions rests largely on HPE. Furthermore, GLI-M must be differentiated from metastatic lesions to the brain arising from solid tumors in other organs. We describe a blood-based test which detects GLI-M with high sensitivity and differentiates it from benign brain tumours (BBT) and brain metastases. The test is based on fluorescent multiplexed immunocytochemical (ICC) profiling for identification of Circulating Glial Cells (CGCs) and Circulating (Epithelial) Tumor Cells (CTCs) enriched from peripheral blood. The performance characteristics of the test were established in analytical validation as well as clinical studies. In an initial case-control study with discrete training (n = 31 BBT and n = 101 GLI-M) and test (n = 13 BBT and n = 44 GLI-M) sets, our platform showed 100% sensitivity and 100% specificity in identifying and differentiating GLI-M from BBT in the test set. In a prospective study of 68 individuals presenting with ICSOL, the test had 100% sensitivity and 100% specificity for identifying and differentiating GLI-M (n = 56) and BBT (n = 12). Finally, in a subset analysis of 586 samples, the test accurately identified samples from GLI-M (n = 40), BBT (n = 22), epithelial malignancies (EPI- M, n = 24) and healthy individuals (n = 500), with no false positive or false negative findings. The performance characteristics of this blood-based platform support its utility in clinical practice for diagnostic triaging of individuals presenting with ICSOL and facilitating more effective diagnosis compared to standard of care.Competing Interest StatementThe authors Kevin O'Neill, Nelofer Syed, Timothy Crook, Sudhir Dubey, Mahadev Potharaju, Sewanti Limaye, Anantbhushan Ranade, Giulio Anichini have declared no conflicts of interest. The authors Darshana Patil, Sudha S Murthy, Dadasaheb Akolkar, Pooja Fulmali, Vineet Datta, Sachin Apurwa, Jinumary John, Ajay Srinivasan are employees of Datar Cancer Genetics Private Limited. Rajan Datar is the founder of Datar Cancer Genetics Private Limited.Funding StatementThis study did not receive any external funding. The entire study was funded by Datar Cancer Genetics Private Limited.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All biological samples were obtained from participants in three studies, GlioLENS with CTRI number CTRI/2019/02/017663 (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31387), TRUEBLOOD with CTRI number CTRI/2019/03/017918 (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31879) and RESOLUTE with CTRI number CTRI/2019/01/017219 (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30733). Datar Cancer Genetics Limited Institutional Ethics Committee of Datar Cancer Genetics Private Limited gave ethical approval for GlioLENS, TRUEBLOOD and RESOLUTE. Institutional Ethics Committee, Clinical Studies of Apollo Hospitals, Hyderabad gave ethical approval for GlioLENS. All participants provided their written informed consent. All studies were performed in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript and its supplementary file.